The estimated Net Worth of Robert J Md Lefkowitz is at least $170 Thousand dollars as of 28 April 2024. Robert Lefkowitz owns over 8,032 units of Lexicon Pharmaceuticals Inc stock worth over $81,735 and over the last 18 years he sold LXRX stock worth over $0. In addition, he makes $88,755 as Independent Director at Lexicon Pharmaceuticals Inc.
Robert has made over 5 trades of the Lexicon Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,032 units of LXRX stock worth $13,574 on 28 April 2024.
The largest trade he's ever made was exercising 10,638 units of Lexicon Pharmaceuticals Inc stock on 24 April 2021 worth over $17,978. On average, Robert trades about 1,612 units every 67 days since 2007. As of 28 April 2024 he still owns at least 48,364 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Robert Lefkowitz stock trades at the bottom of the page.
Dr. Robert J. Lefkowitz M.D. serves as Independent Director of the Company. Dr. Lefkowitz has been a director since February 2001. Dr. Lefkowitz is the James B. Duke Professor of Medicine, professor of biochemistry and a Howard Hughes Medical Institute investigator at Duke University Medical Center, where he has served on the faculty since 1973. Dr. Lefkowitz is a member of the National Academy of Sciences and has received more than 50 major awards for his research, including the 2012 Nobel Prize in Chemistry, the Shaw Prize, the Albany Medical Center Prize and the 2007 National Medal of Science. Dr. Lefkowitz received his B.A. from Columbia University and his M.D. from Columbia University College of Physicians and Surgeons.
As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Robert Lefkowitz at Lexicon Pharmaceuticals Inc is $88,755. There are 15 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
Robert Lefkowitz is 76, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2001. There are 3 older and 16 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
Robert's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc..., and Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: